N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer. Examples of these drugs include EPI-001, EPI-506, and BAY-1024767.
References
N-Terminal domain antiandrogen Wikipedia(Text) CC BY-SA